Allurion announces submission of pma to fda and additional analyses from pivotal audacity study that meet both endpoints

Natick, mass.--(business wire)---- $alur--allurion technologies, inc. (nyse: alur), a pioneer in metabolically healthy weight loss, today announced submission of the fourth and final module of the pre-market approval (pma) application to the food & drug administration (fda) and additional, supportive analyses from the audacity study that meet both of the pre-specified co-primary endpoints. topline results announced previously showed that the audacity study met its first co-primary endpoint related to.
ALUR Ratings Summary
ALUR Quant Ranking